Oculis Shares Are Trading Higher After the Company Announced It Expanded Its DIAMOND Program With Global Retina Experts and Is Accelerating Its Phase 3 Trials for DME Treatment.
Oculis Shares Are Trading Higher After the Company Announced It Expanded Its DIAMOND Program With Global Retina Experts and Is Accelerating Its Phase 3 Trials for DME Treatment.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated